 The FDA has granted Fast Track Designation for VBI Vaccines Incs NASDAQ: VBIV VBI-1901, its cancer vaccine immunotherapeutic candidate to treat recurrent glioblastoma GBM patients with first tumor recurrence. The company also announced the most recent tumor response and overall survival OS data from the Phase 12a study at the American Society of Clinical Oncology Annual Meeting. 